Department of Pathology, Galveston National Laboratory and Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.
Publications dans "Arénavirus de l'Ancien Monde" :
Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.
CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Institut National de la Santé et de la Recherche Médicale U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5308, École Normale Supérieure de Lyon, Lyon, France.
Publications dans "Arénavirus de l'Ancien Monde" :
Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France. sylvain.baize@pasteur.fr.
CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Institut National de la Santé et de la Recherche Médicale U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5308, École Normale Supérieure de Lyon, Lyon, France. sylvain.baize@pasteur.fr.
Publications dans "Arénavirus de l'Ancien Monde" :
Department of Pathology, Galveston National Laboratory and Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.
Publications dans "Arénavirus de l'Ancien Monde" :
Department of Pathology, Galveston National Laboratory and Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA chhuang@utmb.edu.
Publications dans "Arénavirus de l'Ancien Monde" :
Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
Laboratory of Parasitology, Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, North 18 West 9, Kita-ku, Sapporo 060-0818, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
Department of Diseases Control, School of Veterinary Medicine, The University of Zambia, P.O. Box 32379, Lusaka 10101, Zambia.
Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
One Health Research Center, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, North 20 West 10, Kita-ku, Sapporo 001-0020, Japan.
Publications dans "Arénavirus de l'Ancien Monde" :
INTRODUCTION: Parkinson disease (PD) affects approximately 1% of women and men worldwide, particularly older than 60 years. It is a multisystem and neurodegenerative disease with genetics and environm...
To review the published literature on the use of levodopa/carbidopa to augment the treatment of amblyopia....
Literature searches for English language studies were last conducted in October 2022 in the PubMed database with no date restrictions. The combined searches yielded 55 articles, of which 23 were revie...
The duration of treatment was limited to 3 to 16 weeks because of concern about long-term adverse effects such as tardive dyskinesia. This complication was not reported in any of the study participant...
The best available evidence is currently insufficient to show that augmenting amblyopia therapy using up to 16 weeks of levodopa/carbidopa will result in meaningful improvement in visual acuity. Given...
Levodopa-carbidopa intestinal gel infusion (LCIG) is a therapeutic option for advanced Parkinson disease (PD) patients with troublesome motor complications, unresponsive to conventional oral treatment...
A cohort of LCIG patients underwent genetic testing. The motor and neuropsychological outcomes of LCIG were retrospectively analyzed....
Fifty-six patients were analyzed, nine of them (15%) had at least one mutation/variant in a PD-associated gene: five GBA1, two SNCA, one LRRK2, one PRKN; 13 (23%) carried the BDNF Val66Met polymorphis...
Overall, we observed a significant benefit in terms of motor complications in our cohort, including patients carrying genetic mutations/variants. Due to the small sample and limited number of patients...
Dysphagia is common in advanced phases of Parkinson disease (PD), and is a risk factor for aspiration pneumonia. Nonetheless, dysphagia has been poorly investigated in PD patients treated with levodop...
We retrospectively evaluated 95 consecutive PD patients treated with LCIG. Kaplan-Meier and log-rank test were used to compare mortality in patients with dysphagia from others. Cox regression was used...
A significantly higher mortality rate was observed in patients with dysphagia. In the Cox model, dysphagia was the only feature significantly associated with mortality (95%CI 2.780-20.609; p < 0.001)....
Dysphagia significantly increased the risk of death in our cohort of LCIG-treated patients, independently from other relevant features such as age, disease duration, dementia, and hallucinations. Thes...
Levodopa and carbidopa are reported to be degraded by magnesium oxide (MgO), which is often used as a laxative for patients with Parkinson's disease (PD). Ascorbic acid (AsA) can stabilize levodopa an...
The effect of AsA was evaluated using in vitro examinations, compared with lemon juice, and by measuring the plasma concentration of levodopa in a patient with PD....
In vitro experiments showed that the relative concentrations of levodopa remained almost constant, and the relative concentrations of carbidopa decreased with time with addition of MgO. AsA mitigated ...
AsA can mitigate the degradation of carbidopa induced by MgO and may contribute to improving the bioavailability of levodopa in patients with PD....
Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment for late-stage Parkinson's disease (PD) but had not been evaluated in levodopa-responsive patients with the parkinsonian variant of m...
In a retrospective, single-center study, we analyzed clinical and treatment-related data for all patients with MSA-P or PD treated with LCIG between December 2004 and November 2017. Adverse events (AE...
7 MSA-P and 63 PD patients had been treated with LCIG for a median [interquartile range] period of 31 [16;43] and 19 [8;45] months, respectively. There were no significant intergroup differences in sa...
LCIG treatment is feasible in MSA-P patients with severe motor complications. The safety profile is similar to that seen in PD....
Patients with advanced Parkinson's disease (APD) commonly experience motor and nonmotor symptoms (NMS) associated with functional limitations and decreased quality of life. We compared motor and nonmo...
Data from COSMOS, a large, real-world, retrospective and cross-sectional, observational study on LCIG and comedication in APD were obtained from medical records and a single patient visit for patients...
Data for 401 patients were included in this subanalysis. At the patient visit there were 35 patients on 24-h LCIG and 366 on 16-h LCIG. "Off" time and dyskinesia (duration and severity) were reduced i...
LCIG 24-h infusion may be a useful treatment option, when clinically justified, for select patients with APD....
NCT03362879....
We are always looking for the big breakthrough, ideally a cure for our advanced Parkinson's disease (aPD) patients. As long as this does not happen we must optimize the existing therapy, because many ...
The treatment of Parkinson's disease (PD) is still symptomatic since disease-modifying treatments for PD are not available. Oral levodopa is the gold standard for the treatment of PD motor symptoms. H...
A double-blind, placebo-controlled, randomized, crossover, phase I, pharmacokinetic study with 25 healthy volunteers was conducted. In addition, a semi-mechanistic pharmacokinetic model was built to t...
The effect of increased carbidopa doses 50 and 100 mg on the total exposure (AUC) of 100 mg IR levodopa was +29% and +36%, respectively, when entacapone was co-administered. Without entacapone, the co...
Increasing carbidopa doses significantly increased the exposure and reduced the fluctuation of IR levodopa in plasma during simultaneous COMT inhibition with entacapone. Theoretical pharmacokinetic si...
Herein, to monitor the concentration of carbidopa in an aqueous solution, an analytical approach based on electrode surface modification by Pt/SWCNTs as a sensor has been proposed. Pt/SWCNTs was synth...
